Related Experiment Video

Updated: Mar 24, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

10.7K

Relationship between HLA-DRB1 allele polymorphisms and familial aggregations of hepatocellular carcinoma

S Ma1, J Wu1, J Wu1

  • 1Department of Infectious Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, P.R.C.

Current Oncology (Toronto, Ont.)
|March 12, 2016
PubMed

Insights

Genetic factors in familial hepatocellular carcinoma (fhcc) may involve specific HLA-DRB1 alleles. Lower frequencies of DRB1*11 and DRB1*12 alleles were observed in fhcc families, suggesting a potential risk factor.

Area of Science:

  • Immunogenetics
  • Cancer Epidemiology
  • Human Leukocyte Antigen (HLA) System

Background:

  • Familial aggregation of hepatocellular carcinoma (fhcc) suggests a potential genetic component.
  • The Human Leukocyte Antigen (HLA) system, particularly HLA-DRB1 alleles, plays a crucial role in immune response and has been implicated in various cancers.

Purpose of the Study:

  • To investigate the association between HLA-DRB1 allele polymorphisms and the familial aggregation of hepatocellular carcinoma (fhcc).

Main Methods:

  • Genotyping of HLA-DRB1 alleles was performed using polymerase chain reaction sequence-specific primers.
  • 130 members from families with multiple liver cancer patients and 130 members from cancer-free families were analyzed.
  • Genotype frequencies were compared between the fhcc and no-cancer groups.

Main Results:

  • The frequencies of HLA-DRB1*11 and HLA-DRB1*12 alleles were significantly lower in the fhcc group compared to the no-cancer group (p < 0.05).
  • Odds ratios for DRB1*11 and DRB1*12 were 0.286 and 0.493, respectively, indicating a potential protective effect or reduced risk.
  • No statistically significant differences in the frequencies of the other nine studied HLA-DRB1 alleles were found between the groups.

Conclusions:

  • The study suggests that a deficiency in HLA-DRB1*11 and HLA-DRB1*12 alleles may represent a genetic risk factor for fhcc in the Guangxi Zhuang Autonomous Region.
  • These findings contribute to understanding the genetic underpinnings of fhcc and highlight specific HLA-DRB1 alleles for further investigation.
Abstract

Keywords:
HLA-DRB1 allelesfamilial aggregationhepatocellular carcinomapcr-ssppolymorphisms

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.1K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.6K
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
38.7K
Genetic Lingo01:11

Genetic Lingo

Overview
117.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108